The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.

In a general aspect, an apparatus can include a first carbon nanotube array that is patterned to define a first electrode having a first plurality of electrode segments. The apparatus can also include a second carbon nanotube array that is patterned to define a second electrode having a second plurality of electrode segments. The second plurality of electrode segments can be interdigitated with the first plurality of electrode segments. The apparatus can further include a biorecognition agent disposed on a surface of the first electrode and disposed on a surface of the second electrode. The first plurality of electrode segments can each have a height-to-width aspect ratio of at least 1 to 1.

Flow cytometry is used for diagnosis of infectious diseases by an analysis of cell mediated immune responses to specific infective agent antigens. Apparatus and methods of advanced flow cytometry are utilized to detect cell mediated immune responses to the presence of specific antigens from infective agents, such as bacteria, protozoa, viruses, helminth, prions. In some embodiments, methods as provided herein can be utilized in vitro to diagnose multiple infections within individuals.

Flow cytometry is used for diagnosis of infectious diseases by an analysis of cell mediated immune responses to specific infective agent antigens. Apparatus and methods of advanced flow cytometry are utilized to detect cell mediated immune responses to the presence of specific antigens from infective agents, such as bacteria, protozoa, viruses, helminth, prions. In some embodiments, methods as provided herein can be utilized in vitro to diagnose multiple infections within individuals.

A method for preparing a meso crystal of silver oxide containing silver peroxide is provided. A quantum crystal of silver thiosulfate complex on a substrate or a particle made of copper metal or copper alloy is subjected to treating by an alkaline aqueous solution containing halogen ion to obtain a meso crystal of silver oxide containing the silver peroxide. The meso crystal of silver oxide having nanometer scale, containing a silver peroxide, the silver oxide nanocrystal being a superstructure three-dimensionally arranged in the shape of a neuron provided with properties being negatively charged in water and able to be reduced to a silver nanoparticle by a laser radiation.

Bead-based analytical assays suitable for detecting changes in the abundance of target analytes in biological samples are disclosed. In an embodiment, an assay involves incubating a sample with one or several beads that are capable of binding several distinct analytes in an amount sufficient for detection by mass spectrometry from a single bead.

The invention provides anti-Tau antibodies and methods of using the same.

The present invention relates to a biomarker for the non-invasive diagnosis of kidney transplantation rejection and use thereof, and particularly to: a biomarker composition and kit for diagnosing antibody-mediated rejection after kidney transplantation or predicting the prognosis of a patient after kidney transplantation, comprising any one or more proteins selected from the group consisting of LBP and CST3, or gene(s) encoding for the same; a method for providing information required for diagnosing antibody-mediated rejection after kidney transplantation or predicting the prognosis of a patient after kidney transplantation, by using the marker composition; a method for providing information required for determining a therapy for rejection after kidney transplantation; a method for the diagnosis and treatment of antibody-mediated rejection after kidney transplantation; and a method for screening for a therapeutic agent for antibody-mediated rejection after kidney transplantation.

Disclosed herein are methods of allergen testing and IgG depletion. In some embodiments, testing for IgE antibodies specific for an allergen may be improved by first depleting IgG in a sample. In some embodiments, IgG may be depleted using Biotinylated Protein G (bPG) and streptavidin (SA).

The present disclosure relates to method for screening mesenchymal stem cell-derived, neuronal regeneration-promoting cells having neuronal regeneration activity and a pharmaceutical composition containing the neuronal regeneration-promoting cells. The neuronal regeneration-promoting cells of the present disclosure are completely different from stem cells in terms of the expression pattern of a CD marker and exhibit an excellent neuronal regeneration effect. Accordingly, they can be applied in various fields for preventing or treating neurological diseases.